Drug Free Solution Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Drug Free Solution's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Healthcare Industry Growth | 8.5% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 28 Feb 2014 |
Recent past performance updates
No updates
Recent updates
No updates
In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Drug Free Solution has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
Show sectionRevenue & Expenses BreakdownBeta
How Drug Free Solution makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
28 Feb 14 | 0 | -1 | 1 | 0 |
30 Nov 13 | 0 | -1 | 0 | 0 |
31 Aug 13 | 0 | -1 | 0 | 0 |
31 May 13 | 0 | -1 | 1 | 0 |
28 Feb 13 | 0 | 0 | 0 | 0 |
30 Nov 12 | 0 | -1 | 1 | 0 |
Quality Earnings: Insufficient data to determine if DSOL has high quality earnings.
Growing Profit Margin: Insufficient data to determine if DSOL's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if DSOL's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare DSOL's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if DSOL's earnings growth over the past year exceeded the Healthcare industry average.
Return on Equity
High ROE: DSOL has a negative Return on Equity (0%), as it is currently unprofitable.